Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer.

Protein for Prediction of Clinical Benefit of Tamoxifen Therapy in Patients with Advanced Breast Cancer, Lambert C.J. Dorssers, Nicolai Grebenchtchikov, Arend Brinkman, Maxime P. Look, Jan G.M. Klijn, Anneke GeurtsMoespot, Paul N. Span, John A. Foekens, and C.G.J. (Fred) Sweep ( Department of Pathology, Division of Molecular Biology, and 3 Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, The Netherlands; 2 Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands; * address correspondence to this author at: Department of Chemical Endocrinology, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands; fax 31243541484, e-mail [email protected])